Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875923 | 1.00 | PRKAA2 (0.36) | PRKAA2MAPTRECQLTSHRALDH1A1 | |
| SCHEMBL20876032 | 1.00 | PRKAA2 (0.36) | PRKAA2MAPTRECQLTSHRALDH1A1 | |
| SCHEMBL20875948 | 0.89 | MAPT (0.36) | MAPTRECQLTSHRALDH1A1KLK7 | |
| SCHEMBL22279816 | 0.89 | MAPT (0.36) | MAPTRECQLTSHRALDH1A1KLK7 | |
| SCHEMBL22279814 | 0.89 | MAPT (0.36) | MAPTRECQLTSHRALDH1A1KLK7 | |
| SCHEMBL22279633 | 0.85 | TSHR (0.40) | TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL20875866 | 0.85 | TSHR (0.40) | TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL20875942 | 0.80 | SIGMAR1 (0.43) | TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL22279884 | 0.80 | SIGMAR1 (0.43) | TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL20876049 | 0.80 | PRKAA2 (0.40) | PRKAA2MAPTRECQLTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | PLA2G1B, PLA2G4A, PLA2G4C | PRKAA2 3631/4885MAPT 4574/4885RECQL 51/4885 |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G4A, PLA2G4C | PRKAA2 3631/4885MAPT 4574/4885RECQL 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.